October 22, 2024 12:31 PM EDT

Samsung Bio inks largest deal yet worth $1.24B with unnamed Asian pharma

Anna Brown

News Reporter

Samsung Biologics has so far secured at least five major contracts this year, and its latest with an unnamed Asia-based pharmaceutical company is its largest …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Samsung Bio inks largest deal yet worth $1.24B with unnamed Asian pharma

Anna Brown

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Updated: Pfizer's activist says board must 'hold management accountable' for R&D shortcomings

Ahead of Novo’s CagriSema readout, Lilly returns to a promising new class of obesity drugs

Roche, Genentech end anti-tau Alzheimer’s drug collaboration with UCB

Editas pivots away from ex vivo sickle cell therapy in favor of in vivo approach

AvenCell gets $112M to build switchable CAR-T therapies for ‘the last frontier’ of blood cancers

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Sam­sung Bio inks largest deal yet worth $1.24B with un­named Asian phar­ma

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Samsung Bio inks largest deal yet worth $1.24B with unnamed Asian pharma